E. Cammarata, “Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits”, Dermatol Pract Concept, vol. 15, no. 3, p. 5845, Jul. 2025, doi: 10.5826/dpc.1503a5845.